Artwork

コンテンツは Flot.bio によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Flot.bio またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!

Sean Marett 🇩🇪 | BioNTech, Art of Dealmaking | E25

1:14:55
 
シェア
 

Manage episode 453222432 series 3470295
コンテンツは Flot.bio によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Flot.bio またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal

We’re in Hamburg with Sean Marett, who has been instrumental to the success of BioNTech for 12 years.

We talked about the secrets behind BioNTech’s success. We also talked about the art of dealmaking and working with China.

⭐️ ABOUT THE SPEAKER

Sean joined BioNTech in 2012 as part of the Management Board. He was instrumental in the growth of the company and global expansion through business development and product commercialization. Prior to BioNTech Sean worked in top companies such as GlaxoSmithKline, Pfizer, Evotec, and Lorantis. I first met Sean in 2015 in Berlin, when BioNTech had no website, but was already the largest private biotech in Europe. Now Sean has retired from BioNTech after 12 years but still aids the company as a specialist consultant.

🔗 LINKS MENTIONED

- BioNTech Announces Planned Retirement of Sean Marett: https://investors.biontech.de/news-releases/news-release-details/biontech-announces-planned-retirement-sean-marett

- BioNTech pays $800M to take control of potential Keytruda killer: https://www.fiercebiotech.com/biotech/biontech-pays-800m-take-control-potential-keytruda-killer

- Sean Marett, COO at BioNTech, on the Future of mRNA Therapies - 2015: https://www.youtube.com/watch?v=6zrDKRvsAEU

📜 TRANSCRIPT

Read the full transcript here:

💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

- Newsletter: http://eepurl.com/h_fnmH

- LinkedIn: https://www.linkedin.com/company/flot-bio/

- X (Twitter): https://x.com/FlotBio

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.

⏰ TIMESTAMPS

- [00:00:00] Intro

- [00:01:45] Sean Marett stepping down as CBO of BioNTech

- [00:05:10] From Pfizer to BioNTech

- [00:15:28] Building a biotech in Mainz

- [00:29:02] The art of biotech dealmaking

- [00:45:29] Mistakes in dealmaking

- [00:57:45] Biotech dealmaking in China

- [01:04:25] Managing energy

- [01:08:17] Quickfire

- [01:13:57] Thanks for listening

  continue reading

26 つのエピソード

Artwork
iconシェア
 
Manage episode 453222432 series 3470295
コンテンツは Flot.bio によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Flot.bio またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal

We’re in Hamburg with Sean Marett, who has been instrumental to the success of BioNTech for 12 years.

We talked about the secrets behind BioNTech’s success. We also talked about the art of dealmaking and working with China.

⭐️ ABOUT THE SPEAKER

Sean joined BioNTech in 2012 as part of the Management Board. He was instrumental in the growth of the company and global expansion through business development and product commercialization. Prior to BioNTech Sean worked in top companies such as GlaxoSmithKline, Pfizer, Evotec, and Lorantis. I first met Sean in 2015 in Berlin, when BioNTech had no website, but was already the largest private biotech in Europe. Now Sean has retired from BioNTech after 12 years but still aids the company as a specialist consultant.

🔗 LINKS MENTIONED

- BioNTech Announces Planned Retirement of Sean Marett: https://investors.biontech.de/news-releases/news-release-details/biontech-announces-planned-retirement-sean-marett

- BioNTech pays $800M to take control of potential Keytruda killer: https://www.fiercebiotech.com/biotech/biontech-pays-800m-take-control-potential-keytruda-killer

- Sean Marett, COO at BioNTech, on the Future of mRNA Therapies - 2015: https://www.youtube.com/watch?v=6zrDKRvsAEU

📜 TRANSCRIPT

Read the full transcript here:

💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

- Newsletter: http://eepurl.com/h_fnmH

- LinkedIn: https://www.linkedin.com/company/flot-bio/

- X (Twitter): https://x.com/FlotBio

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.

⏰ TIMESTAMPS

- [00:00:00] Intro

- [00:01:45] Sean Marett stepping down as CBO of BioNTech

- [00:05:10] From Pfizer to BioNTech

- [00:15:28] Building a biotech in Mainz

- [00:29:02] The art of biotech dealmaking

- [00:45:29] Mistakes in dealmaking

- [00:57:45] Biotech dealmaking in China

- [01:04:25] Managing energy

- [01:08:17] Quickfire

- [01:13:57] Thanks for listening

  continue reading

26 つのエピソード

すべてのエピソード

×
 
Loading …

プレーヤーFMへようこそ!

Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。

 

クイックリファレンスガイド

探検しながらこの番組を聞いてください
再生